APA (7th ed.) Citation

Bouazza, N., Urien, S., Foissac, F., Choupeaux, L., Lui, G., Froelicher Bournaud, L., . . . Epaud, R. (2024). Lumacaftor/Ivacaftor Population Pharmacokinetics in Pediatric Patients with Cystic Fibrosis: A First Step Toward Personalized Therapy. Clinical Pharmacokinetics, 63(3), 333. https://doi.org/10.1007/s40262-023-01342-3

Chicago Style (17th ed.) Citation

Bouazza, Naïm, et al. "Lumacaftor/Ivacaftor Population Pharmacokinetics in Pediatric Patients with Cystic Fibrosis: A First Step Toward Personalized Therapy." Clinical Pharmacokinetics 63, no. 3 (2024): 333. https://doi.org/10.1007/s40262-023-01342-3.

MLA (9th ed.) Citation

Bouazza, Naïm, et al. "Lumacaftor/Ivacaftor Population Pharmacokinetics in Pediatric Patients with Cystic Fibrosis: A First Step Toward Personalized Therapy." Clinical Pharmacokinetics, vol. 63, no. 3, 2024, p. 333, https://doi.org/10.1007/s40262-023-01342-3.